Glioma is the most common central nervous system primary tumor, accounting for about 40％of intracranial tumors. In re-cent years, studies have shown that the human brain is not immune-free zone. The low immunogenicity of the tumor itself, tumor-generated immunosuppressive factors, and the low immunity of tumor patients all contribute to the"immune escape"phenomenon of glioma cells. Dendritic cells (DCs), as the strongest antigen-presenting cells in the body, play an important role in tumor immunotherapy with T-cell recognizing tumor antigens as the core. Therefore, it is necessary to adopt a strategy of culturing and sensitizing DC cells in vitro to increase their number and improve their function before returning to the body for treatment of patients with glioma.
展开▼
